1 |
Bhoiwala, D. L., Kannabiran, V., Hushmendy, S. F., Hahn, A., Heuring, J. M. and Crawford, D. R. 2011. The calcineurin inhibitor RCAN1 is involved in cultured macrophage and in vivo immune response. FEMS Immunol. Med. Microbiol. 61, 103-113.
DOI
|
2 |
Blair, H. C., Teitelbaum, S. L., Ghiselli, R. and Gluck, S. 1989. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245, 855-857.
DOI
|
3 |
Bush, C. R., Havens, J. M., Necela, B. M., Su, W., Chen, L., Yanagisawa, M., Anastasiadis, P. Z., Guerra, R., Luxon, B. A. and Thompson, E. A. 2007. Functional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor gamma and calcium signaling in human colorectal cancer cells. J. Biol. Chem. 282, 23387-23401.
DOI
|
4 |
Cano, E., Canellada, A., Minami, T., Iglesias, T. and Redondo, J. M. 2005. Depolarization of neural cells induces transcription of the Down syndrome critical region 1 isoform 4 via a calcineurin/nuclear factor of activated T cells-dependent pathway. J. Biol. Chem. 280, 29435-29443.
DOI
|
5 |
Corsi, M. M., Ponti, W., Venditti, A., Ferrara, F., Baldo, C., Chiappelli, M. and Licastro, F. 2003. Proapoptotic activated T-cells in the blood of children with Down's syndrome: relationship with dietary antigens and intestinal alterations. Int. J. Tissue React. 25, 117-125.
|
6 |
Davies, K. J., Ermak, G., Rothermel, B. A., Pritchard, M., Heitman, J., Ahnn, J., Henrique-Silva, F., Crawford, D., Canaider, S., Strippoli, P., Carinci, P., Min, K. T., Fox, D. S., Cunningham, K. W., Bassel-Duby, R., Olson, E. N., Zhang, Z., Williams, R. S., Gerber, H. P., Perez-Riba, M., Seo, H., Cao, X., Klee, C. B., Redondo, J. M., Maltais, L. J., Bruford, E. A., Povey, S., Molkentin, J. D., McKeon, F. D., Duh, E. J., Crabtree, G. R., Cyert, M. S., de la Luna, S. and Estivill, X. 2007. Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin. FASEB J. 21, 3023-3028.
DOI
|
7 |
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., Armstrong, A., Shen, V., Bain, S., Cosman, D., Anderson, D., Morrissey, P. J., Peschon, J. J. and Schuh, J. 1999. RANK is essential for osteoclast and lymph node development. Genes. Dev. 13, 2412-2424.
DOI
|
8 |
Fuentes, J. J., Genesca, L., Kingsbury, T. J., Cunningham, K. W., Perez-Riba, M., Estivill, X. and de la Luna, S. 2000. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum. Mol. Genet. 9, 1681-1690.
DOI
|
9 |
Hasegawa, H., Kido, S., Tomomura, M., Fujimoto, K., Ohi, M., Kiyomura, M., Kanegae, H., Inaba, A., Sakagami, H. and Tomomura, A. 2010. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity. J. Biol. Chem. 285, 25448-25457.
DOI
|
10 |
Fuentes, J. J., Pritchard, M. A. and Estivill, X. 1997. Genomic organization, alternative splicing, and expression patterns of the DSCR1 (Down syndrome candidate region 1) gene. Genomics 44, 358-361.
DOI
|
11 |
Hassold, T. J. and Jacobs, P. A. 1984. Trisomy in man. Annu. Rev. Genet. 18, 69-97.
DOI
|
12 |
Hirakawa, Y., Nary, L. J. and Medh, R. D. 2009. Glucocorticoid evoked upregulation of RCAN1-1 in human leukemic CEM cells susceptible to apoptosis. J. Mol. Signal. 4, 6.
DOI
|
13 |
James, I. E., Lark, M. W., Zembryki, D., Lee-Rykaczewski, E. V., Hwang, S. M., Tomaszek, T. A., Belfiore, P. and Gowen, M. 1999. Development and characterization of a human in vitro resorption assay: demonstration of utility using novel antiresorptive agents. J. Bone Miner. Res. 14, 1562-1569.
DOI
|
14 |
Jang, C., Lim, J. H., Park, C. W. and Cho, Y. J. 2011. Regulator of calcineurin 1 Isoform 4 (RCAN1.4) is overexpressed in the glomeruli of diabetic mice. Kor. J. Physiol. Pharmacol. 15, 299-305.
DOI
ScienceOn
|
15 |
Kuroda, Y., Hisatsune, C., Nakamura, T., Matsuo, K. and Mikoshiba, K. 2008. Osteoblasts induce Ca2+ oscillation-independent NFATc1 activation during osteoclastogenesis. Proc. Natl. Acad. Sci. USA 105, 8643-8648.
DOI
|
16 |
Peiris, H., Raghupathi, R., Jessup, C. F., Zanin, M. P., Mohanasundaram, D., Mackenzie, K. D., Chataway, T., Clarke, J. N., Brealey, J., Coates, P. T., Pritchard, M. A. and Keating, D. J. 2012. Increased expression of the glucose-responsive gene, RCAN1, causes hypoinsulinemia, beta-cell dysfunction, and diabetes. Endocrinology 153, 5212-5221.
DOI
|
17 |
Li, J., Sarosi, I., Yan, X. Q., Morony, S., Capparelli, C., Tan, H. L., McCabe, S., Elliott, R., Scully, S., Van, G., Kaufman, S., Juan, S. C., Sun, Y., Tarpley, J., Martin, L., Christensen, K., McCabe, J., Kostenuik, P., Hsu, H., Fletcher, F., Dunstan, C. R., Lacey, D. L. and Boyle, W. J. 2000. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97, 1566-1571.
DOI
|
18 |
Mammucari, C., Tommasi di Vignano, A., Sharov, A. A., Neilson, J., Havrda, M. C., Roop, D. R., Botchkarev, V. A., Crabtree, G. R. and Dotto, G. P. 2005. Integration of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control. Dev. Cell 8, 665-676.
DOI
|
19 |
Minami, T. 2014. Calcineurin-NFAT activation and DSCR-1 auto-inhibitory loop: how is homoeostasis regulated? J. Biochem. 155, 217-226.
DOI
|
20 |
Porta, S., Serra, S. A., Huch, M., Valverde, M. A., Llorens, F., Estivill, X., Arbones, M. L. and Marti, E. 2007. RCAN1 (DSCR1) increases neuronal susceptibility to oxidative stress: a potential pathogenic process in neurodegeneration. Hum. Mol. Genet. 16, 1039-1050.
DOI
|
21 |
Rothermel, B. A., Vega, R. B. and Williams, R. S. 2003. The role of modulatory calcineurin-interacting proteins in calcineurin signaling. Trends. Cardiovasc. Med. 13, 15-21.
DOI
|
22 |
Sun, X., Wu, Y., Herculano, B. and Song, W. 2014. RCAN1 overexpression exacerbates calcium overloading-induced neuronal apoptosis. PLoS One 9, e95471.
DOI
|
23 |
Ryeom, S., Greenwald, R. J., Sharpe, A. H. and McKeon, F. 2003. The threshold pattern of calcineurin-dependent gene expression is altered by loss of the endogenous inhibitor calcipressin. Nat. Immunol. 4, 874-881.
DOI
|
24 |
Sanna, B., Brandt, E. B., Kaiser, R. A., Pfluger, P., Witt, S. A., Kimball, T. R., van Rooij, E., De Windt, L. J., Rothenberg, M. E., Tschop, M. H., Benoit, S. C. and Molkentin, J. D. 2006. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc. Natl. Acad. Sci. USA 103, 7327-7332.
DOI
|
25 |
Seeman, E. and Delmas, P. D. 2006. Bone quality-the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354, 2250-2261.
DOI
|
26 |
Wei, S., Teitelbaum, S. L., Wang, M. W. and Ross, F. P. 2001. Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors. Endocrinology 142, 1290-1295.
|
27 |
Weischenfeldt, J. and Porse, B. 2008. Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. CSH Protoc 2008, pdb prot5080.
|
28 |
Wu, H., Kao, S. C., Barrientos, T., Baldwin, S. H., Olson, E. N., Crabtree, G. R., Zhou, B. and Chang, C. P. 2007. Down syndrome critical region-1 is a transcriptional target of nuclear factor of activated T cells-c1 within the endocardium during heart development. J. Biol. Chem. 282, 30673-30679.
DOI
|